scholarly journals Association between the IL10 rs1800896 Polymorphism and Tardive Dyskinesia in Schizophrenia

2020 ◽  
Vol 17 (10) ◽  
pp. 1031-1036
Author(s):  
Kwang-Yeon Choi ◽  
Jeong Min Choo ◽  
Youn-Jung Lee ◽  
Yujin Lee ◽  
Chul-Hyun Cho ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Melting Curve ◽  
Gene Promoter ◽  
Interleukin 10 ◽  
Allele Carrier ◽  
High Resolution Melting Curve ◽  
Its Gene ◽  
Il10 Gene ◽  
Schizophrenic Patients

Objective Interleukin-10 (IL-10) is a major immunoregulatory cytokine and its gene plays a fundamental role in anti-inflammatory and immunosuppressive activity. This study aimed to examine the association between the IL10 gene promoter -1082G/A polymorphism (rs1800896) and tardive dyskinesia (TD) in schizophrenia.Methods Two hundred and eighty unrelated Korean schizophrenic patients participated in this study (105 TD and 175 non-TD patients). TD was diagnosed using the Research Diagnostic Criteria for TD and Abnormal Involuntary Movement Scale (AIMS). Genotyping was performed by RT-PCR and high-resolution melting curve analysis.Results The distributions of genotypic frequencies did not differ between patients with and without TD (χ<sup>2</sup>=4.33, p=0.115). However, allelic frequencies of the two groups were different (χ<sup>2</sup>=4.45, p=0.035); the A allele frequency was higher in TD. The total AIMS scores of the three genotypes were not different (F=1.33, p=0.266). However, the total AIMS scores of the A allele carrier and the A allele non-carrier were significantly different (t=5.79, p<0.001). Logistic regression analaysis showed that <i>IL10</i> -1082G/A genotype significantly predicts presence of TD (p=0.045) after adjusting for covariates such as age and treatment duration.Conclusion This finding suggests that the A allele of rs1800896 may be associated with TD development following a low IL-10 function.

scholarly journals Association of IL10 gene promoter polymorphisms with risks of gastric cancer and atrophic gastritis

2018 ◽  
Vol 46 (12) ◽  
pp. 5155-5166 ◽  
Author(s):  
Sa Liu ◽  
Jing-Wei Liu ◽  
Li-Ping Sun ◽  
Yue-Hua Gong ◽  
Qian Xu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Atrophic Gastritis ◽  
Demographic Data ◽  
Gene Promoter ◽  
Interleukin 10 ◽  
Recessive Model ◽  
Enzyme Linked Immunosorbent Assay ◽  
Promoter Polymorphisms ◽  
Increased Risk ◽  
Il10 Gene

Objective To investigate the association between polymorphisms of the interleukin 10 ( IL10) gene and risk of gastric cancer (GC) and atrophic gastritis (AG). Methods This study enrolled patients with GC, patients with AG and healthy control subjects. Demographic data were collected and the IL10 gene –1082A/G, –819C/T and –592A/C polymorphisms were genotyped. An enzyme-linked immunosorbent assay was performed to detect Helicobacter pylori infection. Results The study enrolled 556 participants including 208 in the GC group, 116 in the AG group and 232 controls (CON group). In a recessive model of the IL10–819C/T polymorphism, a significantly decreased risk of GC was found compared with AG and non-cancer subjects, respectively (AG→GC: odds ratio OR 0.41; non-cancer→GC: OR 0.57). The CC genotype demonstrated a significantly increased risk of AG compared with CON. Similar significant results were detected in males and H. pylori-negative subgroups. The ACC haplotype was associated with a decreased risk of GC compared with AG. The ATC haplotype was associated with a decreased risk of AG compared with the CON group, but it was associated with an increased risk of GC compared with AG. Conclusion The IL10 gene promoter –819C/T (rs1800871) polymorphism was associated with the risk of GC and AG in a Chinese population.

Interleukin-10 Gene Promoter Polymorphisms and Susceptibility to Asthma: Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Danyal Imani ◽  
Navid Dashti ◽  
Arash Parvari ◽  
Sajad Shafiekhani ◽  
Fatemeh Alebrahim ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Gene Promoter ◽  
Interleukin 10 ◽  
Promoter Polymorphisms

Serum immunoglobulins in tardive dyskinesia — implication for pathogenesis of the syndrome

1990 ◽  
Vol 7 (2) ◽  
pp. 145-146 ◽  
Author(s):  
Hanafy Youssef
Keyword(s):  
Tardive Dyskinesia ◽  
Serum Immunoglobulin ◽  
Neuroleptic Treatment ◽  
Serum Immunoglobulins ◽  
Schizophrenic Patients ◽  
Immunological System

AbstractLevels of immunoglobulins were measured in 32 schizophrenic patients with tardive dyskinesia and 34 schizophrenic patients without tardive dyskinesia. The duration of neuroleptic treatment in years was similar in the two groups. The serum immunoglobulin concentrations (mg%) were found to be significantly different in the two groups; IGA and IGM levels were higher in patients with tardive dyskinesia. The present results may be explained on the basis of dysfunction of the immunological system in tardive dyskinesia.

Treatment of tardive dyskinesia

1978 ◽  
Vol 16 (14) ◽  
pp. 55-56
Keyword(s):  
Tardive Dyskinesia ◽  
Late Onset ◽  
Psychiatric Patients ◽  
Term Treatment ◽  
Neuroleptic Drugs ◽  
Abnormal Movements ◽  
Long Term Treatment ◽  
The Face ◽  
Schizophrenic Patients

Neuroleptic drugs cause many forms of extra-pyramidal syndromes. One of these, tardive dyskinesia,1 occurs only after the patient has been taking the drug for some time (‘tardive’ refers to the late onset). The movements are involuntary and repetitive usually involving the face and tongue, but they may also affect the limbs and trunk. Tongue protrusion, licking and smacking of the lips, sucking and chewing movements, grimacing, grunting, blinking and furrowing of the forehead have all been described and attributed to long-continued medication with neuroleptic drugs of the phenothiazine, butyrophenone and thioxanthene groups. The patient can inhibit the movements, but anxiety makes them worse. Many of these symptoms were noticed in schizophrenic patients before neuroleptic drugs were introduced2 and they can occur in otherwise normal untreated elderly people. Nevertheless it is generally accepted that in most cases tardive dyskinesia is an unwanted effect of neuroleptic medication. Despite suggestions to the contrary, the abnormal movements are not necessarily associated with high dosage of neuroleptic drugs or with pre-existing brain damage.3 4 Tardive dyskinesia has been reported in 3–6% of a mixed population of psychiatric patients5 and over half of a group of chronic schizophrenics on long-term treatment.4 The more careful the neurological examination, the greater the apparent incidence.

The management of tardive dyskinesia

1986 ◽  
Vol 24 (7) ◽  
pp. 27-28
Keyword(s):  
Tardive Dyskinesia ◽  
Antipsychotic Drugs ◽  
Disease Process ◽  
Neuroleptic Drug ◽  
Blocking Drug ◽  
Unwanted Effect ◽  
Difficult Condition ◽  
The Face ◽  
Schizophrenic Patients

Dyskinesias are involuntary movements usually of the face and tongue and sometimes of the limbs and trunk. Tardive (delayed) dyskinesia occurs in patients who have been taking an antipsychotic (neuroleptic) drug or, rarely, another central dopamine-receptor-blocking drug such as metoclopramide. It generally occurs only in those treated for longer than a year, although much shorter exposures have been implicated with the antipsychotics. A similar dyskinesia occurred in schizophrenic patients before antipsychotic drugs were introduced, and can occur in healthy untreated elderly people; risk factors include old age, brain damage1 and the schizophrenic disease process.2 Nevertheless, in most patients on an antipsychotic drug (whether psychotic or not), tardive dyskinesia is an unwanted effect of the drug. It occurs in 5–40% of patients on long-term antipsychotic medication.3–5 we discuss here advances in the management of this difficult condition since our last review.6

Association of Polymorphisms in Interleukin-10 Gene Promoter with Autoantibody Production in Patients with Rheumatoid Arthritis

2009 ◽  
Vol 1173 (1) ◽  
pp. 501-508 ◽  
Author(s):  
Petr Nemec ◽  
Monika Pavkova Goldbergova ◽  
Jindra Gatterova ◽  
Anna Vasku ◽  
Miroslav Soucek
Keyword(s):  
Rheumatoid Arthritis ◽  
Gene Promoter ◽  
Interleukin 10 ◽  
Autoantibody Production

scholarly journals Identification of the SARS-CoV-2 Delta variant C22995A using a high-resolution melting curve RT-FRET-PCR

2021 ◽  
pp. 1-11
Author(s):  
Subarna Barua ◽  
Jianfa Bai ◽  
Patrick John Kelly ◽  
Gregg Hanzlicek ◽  
Lance Noll ◽  
...  
Keyword(s):  
High Resolution ◽  
High Resolution Melting ◽  
Melting Curve ◽  
High Resolution Melting Curve
Sign in / Sign up

Export Citation Format

Share Document